High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

被引：3
|
作者：
Heintel, Daniel [1 ]
Bolomsky, Arnold [1 ]
Schreder, Martin [1 ]
Pfeifer, Sabine [1 ]
Zojer, Niklas [1 ]
Jaeger, Ulrich [2 ]
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenhosp, Ctr Oncol & Hematol, Dept Internal Med 1, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2879.2879
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1242 / 1243
页数：2
相关论文
共 50 条
  • [21] Gain of Chromosome 1q is Associated with Early Progression in Multiple Myeloma Patients Treated with Lenalidomide, Bortezomib, and Dexamethasone
    Schmidt, Timothy
    Joseph, Nisha
    Barwick, Benjamin
    Heffner, Leonard T.
    Hofmeister, Craig
    Bernal, Leon
    Dhodapkar, Madhav
    Gupta, Vikas
    Jaye, David
    Chen, Zhengjia
    Boise, Lawrence
    Lonial, Sagar
    Nooka, Ajay
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E76 - E77
  • [22] Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
    Schmidt, Timothy M.
    Barwick, Benjamin G.
    Joseph, Nisha
    Heffner, Leonard T.
    Hofmeister, Craig C.
    Bernal, Leon
    Dhodapkar, Madhav V.
    Gupta, Vikas A.
    Jaye, David L.
    Wu, Jiayi
    Goyal, Subir
    Chen, Zhengjia
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    BLOOD CANCER JOURNAL, 2019, 9 (12)
  • [23] Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Ho Sup Lee
    Kihyun Kim
    Je-Jung Lee
    Sung-Soo Yoon
    Soo-Mee Bang
    Jin Seok Kim
    Hyeon-Seok Eom
    Dok Hyun Yoon
    Yoojin Lee
    Ho-Jin Shin
    Yong Park
    Jae-Cheol Jo
    Won Sik Lee
    Young Rok Do
    Yeung-Chul Mun
    Mark Hong Lee
    Hyo Jung Kim
    Sung-Hyun Kim
    Min Kyoung Kim
    Sung-Nam Lim
    Seong Kyu Park
    Jun Ho Yi
    Jae Hoon Lee
    Chang-Ki Min
    International Journal of Hematology, 2021, 113 : 81 - 91
  • [24] Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Lee, Ho Sup
    Kim, Kihyun
    Lee, Je-Jung
    Yoon, Sung-Soo
    Bang, Soo-Mee
    Kim, Jin Seok
    Eom, Hyeon-Seok
    Yoon, Dok Hyun
    Lee, Yoojin
    Shin, Ho-Jin
    Park, Yong
    Jo, Jae-Cheol
    Lee, Won Sik
    Do, Young Rok
    Mun, Yeung-Chul
    Lee, Mark Hong
    Kim, Hyo Jung
    Kim, Sung-Hyun
    Kim, Min Kyoung
    Lim, Sung-Nam
    Park, Seong Kyu
    Yi, Jun Ho
    Lee, Jae Hoon
    Min, Chang-Ki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) : 81 - 91
  • [25] CLINICAL IMPACT OF THE PLASMA LENALIDOMIDE CONCENTRATION AND THE ANALYSIS OF ANTI-TUMOR IMMUNE RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE AND DEXAMETHASONE THERAPY
    Kobayashi, T.
    Miura, M.
    Niioka, T.
    Fujioka, Y.
    Abumiya, M.
    Ikeda, S.
    Yoshioka, T.
    Kameoka, Y.
    Nishikawa, H.
    Takahashi, N.
    HAEMATOLOGICA, 2017, 102 : 795 - 795
  • [26] Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
    Qian, Xiaozhong
    Dimopoulos, Meletios A.
    Amatangelo, Michael
    Bjorklund, Chad
    Towfic, Fadi
    Flynt, Erin
    Weisel, Katja C.
    Ocio, Enrique M.
    Yu, Xin
    Peluso, Teresa
    Sternas, Lars
    Zaki, Mohamed
    Moreau, Philippe
    Thakurta, Anjan
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 462 - 470
  • [27] Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)
    Ailawadhi, Sikander
    Larkins, Gail
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    BLOOD, 2017, 130
  • [28] Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
    Otani, Yuki
    Zhao, Yunqi
    Wang, Guanyu
    Labotka, Richard
    Rogge, Mark
    Gupta, Neeraj
    Vakilynejad, Majid
    Bottino, Dean
    Tanigawara, Yusuke
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (12): : 2124 - 2136
  • [29] SURVIVAL EFFECT OF ERYTHOPOIETIC AGENTS AND VENOUS THROMBOEMBOLISM (VTE) IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE AND HIGH-DOSE DEXAMETHASONE
    Zangari, M.
    Tricot, G.
    Polavaram, L.
    Finlayson, A.
    Zhan, F.
    Knight, R.
    Fu, T.
    Weber, D.
    Dimopoulos, M.
    Niesvizky, R.
    Fink, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 158 - 159
  • [30] Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pboRd) in the Phase 3 TOURMALINE-MM2 Trial
    Richardson, Paul G.
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Kumar, Arun
    Twumasi-Ankrah, Philip
    Labotka, Richard
    Rifkin, Robert M.
    Lonial, Sagar
    Kumar, Shaji
    Rajkumar, S. Vincent
    Moreau, Philippe
    BLOOD, 2021, 138
12345